The primary objectives of this analysis were to determine which pharmacokinetic model
most accurately describes the elimination pathways for piperacillin in the presence of …

Standard doses of piperacillin/tazobactam (9–13.5 g over 24 h) administered by continuous
infusion (CI) routinely provide serum concentrations in excess of the susceptibility …

Piperacillin/tazobactam is a new combination of a broad-spectrum penicillin and a beta-
lactamase inhibitor. In studies in healthy volunteers, the pharmacokinetics of piperacillin …

A multiple-dose, open-labelled, randomized, two period crossover human volunteer study
was performed (i) to describe the pharmacokinetic profile and safety profile of piperacillin …

The percentage of the time that the free drug concentration remains above a concentration
threshold (% fT> concentration threshold) has frequently been identified to be the optimal …

Twenty-three generic intravenous piperacillin/tazobactam products were compared for in
vitro activity to the branded formulation (Zosyn®, Wyeth, Philadelphia, PA) by disk diffusion …

The safety of piperacillin/tazobactam was investigated in Phase I and Phase III clinical
studies. In 22 Phase I pharmacokinetic studies, 242 healthy subjects and 232 patients were …

Pharmacokinetic changes are often seen in patients with severe infections. Administration
by continuous infusion has been suggested to optimize antibiotic exposure and …

Background: Prolonging the infusion of a β-lactam antibiotic enhances the time in which
unbound drug concentrations remain above the minimum inhibitory concentration (fT> MIC) …

Study Objective. To compare conventional intermittent dosing regimens of piperacillin‐
tazobactam with prolonged and continuous infusions to determine the optimal dosing …